Macular Degeneration: What Protects Your Vision, and Does AREDS2 Work?

TL;DR: Age-related macular degeneration (AMD) is the leading cause of central vision loss after 50, and the supplement question around it is widely misunderstood. AREDS2, the eye vitamin formula sold at every pharmacy, does a single, specific job well: in people who already have intermediate or advanced AMD, it slows progression to the vision-threatening stage by roughly a quarter. It does not prevent AMD, will not help early or no disease, and cannot bring back lost vision, so taking it without a diagnosis is not evidence-based. What lowers your risk in the first place is behavioral: not smoking (the strongest lever), a Mediterranean diet with leafy greens and fish, and managing blood pressure and weight. If AMD runs in your family, get a dilated eye exam that stages the disease and tells you whether AREDS2 is even for you.

If a parent lost vision to macular degeneration, or you have seen AREDS2 bottles at the pharmacy and wondered whether you should be taking them, this page is for you. Macular degeneration is common and frightening, and the advice around it is a mix of good science and supplement-aisle myth. The short version is that the one proven eye vitamin helps a specific group of people and no one else, and the most powerful prevention has nothing to do with a bottle.

What is macular degeneration?

Macular degeneration is damage to the macula, the small central part of the retina that gives you sharp, straight-ahead vision for reading, faces, and driving. It spares peripheral vision, so it rarely causes total blindness, but it can take the center of your sight. It is the leading cause of irreversible central vision loss in adults over 50 in the developed world, and about 20 million Americans have some degree of it, most of them in the early stages.⁵ Worldwide, the number is projected to reach roughly 288 million by 2040 as populations age.⁴

There are two forms. The dry type makes up about 85 to 90% of cases and is marked by small yellow deposits under the retina called drusen; in its advanced form, patches of retinal cells die off, called geographic atrophy, and central vision fades gradually. The wet type is less common, about 10 to 15%, but causes most of the severe, rapid vision loss, when abnormal blood vessels grow under the retina and leak. Doctors stage the disease as early, intermediate, or advanced, and that stage is what determines whether the eye vitamins help you, as you will see.

What raises your risk of macular degeneration?

Some risk factors you cannot change. Age is the biggest, with risk climbing steeply after 60. Genetics matter a great deal: two gene variants, in genes called CFH and ARMS2, carry most of the inherited risk, which is why a family history of the disease raises your risk meaningfully. European ancestry and light-colored eyes add to it.

The better news is that the strongest changeable risk factor is one you control. Smoking roughly doubles to quadruples the risk of advanced macular degeneration, brings it on years earlier, and even blunts how well the injections for wet AMD work; quitting lowers the risk over time.¹²¹³ Beyond smoking, the same things that age your arteries appear to age your macula: high blood pressure, excess weight, and a poor diet. The role of sunlight and blue light is often raised but remains debated, so UV-blocking sunglasses are a sensible, low-cost habit rather than a proven shield.

Does AREDS2 prevent macular degeneration?

This is the question that sends people to the pharmacy, and the answer surprises most of them: no, AREDS2 does not prevent macular degeneration. Its benefit is narrower and more specific than the marketing suggests.

The story starts with a large trial called AREDS, published in 2001, which tested a high-dose formula of vitamins C and E, beta-carotene, zinc, and copper. In people who already had intermediate AMD, or advanced AMD in one eye, the formula cut the risk of progressing to advanced disease by about 25% over 5 years and reduced significant vision loss by about 19%.¹ The catch, and it is the heart of this whole topic, is that the benefit showed up only in that higher-risk group. People with no AMD or only early AMD got no benefit at all.

A follow-up trial, AREDS2, published in 2013, refined the formula.² It found that adding omega-3 fish oil did nothing, and it swapped out beta-carotene for two plant pigments, lutein and zeaxanthin, which worked at least as well and were safer. Beta-carotene had to go because it raised the risk of lung cancer in smokers and former smokers, echoing earlier trials that found the same harm; in AREDS2, lung cancer occurred in about 2% of those taking beta-carotene versus about 1% of those not taking it, almost all of them former smokers.²⁷

One important caveat belongs here. In AREDS2, the headline comparison for lutein and zeaxanthin did not quite reach statistical significance on its own; the case for the switch rests on secondary analyses and on a 10-year follow-up that found lutein and zeaxanthin slowed progression better than beta-carotene and confirmed the cancer signal.³ So the modern formula is well supported, but it is a story of accumulated evidence rather than a single knockout result.

What AREDS2 does and does not do

It helps to state this plainly, because the misunderstanding is so common. AREDS2 slows the progression to advanced, vision-threatening AMD in people who already have intermediate AMD or advanced AMD in one eye. For that group, it is a proven, well-supported therapy, endorsed by eye doctors.

Here is what it does not do. It does not prevent macular degeneration in someone who does not have it. It will not help early-stage disease, where no benefit has ever been shown. And it cannot restore vision that is already gone; at best it slows further loss. Think of AREDS2 as a brake for a car that is already rolling downhill. It does not work as a fence that keeps the car out of the driveway in the first place. Taking it without an intermediate or advanced diagnosis is not backed by evidence, and for a smoker, the old beta-carotene version was harmful.

What lowers your risk in the first place

If AREDS2 is not prevention, what is? The evidence points to the same habits that protect your heart and brain, which is convenient for anyone already thinking about longevity.

Not smoking is the single highest-yield step, full stop. After that, diet does meaningful work. In the strongest cohort study, people who closely followed a Mediterranean diet had about 40% lower risk of developing advanced macular degeneration.⁶ Leafy greens like spinach and kale supply the same lutein and zeaxanthin found in the eye vitamins, and eating fish a couple of times a week is linked to lower risk.⁸

There is a revealing wrinkle in the fish story. Dietary omega-3, the kind you get from eating fish, is tied to lower AMD risk, yet omega-3 supplements did nothing in the AREDS2 trial. The lesson repeats across nutrition: eat the fish, and do not count on the capsule to stand in for it. Rounding out the list, managing blood pressure and weight and staying active all support the small vessels that feed the retina, which is why eye health and cardiovascular health travel together.

What about treatment for advanced AMD?

For advanced disease, the picture has brightened. Wet AMD, once a near-certain path to central vision loss, is now treated with injections that block a growth factor called VEGF, and they preserve or even improve vision in most treated eyes. It is one of the clear success stories of modern eye care.

Advanced dry AMD, or geographic atrophy, was untreatable until recently. In 2023, two injectable drugs, pegcetacoplan and avacincaptad, became the first treatments approved for it.⁹¹⁰ They modestly slow the growth of the atrophy, by roughly a sixth to a fifth, but the caveats are large: they do not restore vision, they require ongoing injections every one to two months, they have not yet clearly been shown to preserve the vision a person notices day to day, and they carry a rare risk of serious eye inflammation. They are a meaningful first step for a condition that had none, and a decision to weigh carefully with a retina specialist.

Catching the wet form early is valuable, since the injections work best before much vision is lost. A simple home tool called the Amsler grid, and an FDA-cleared home monitoring device for higher-risk patients, can flag the change to wet AMD sooner and preserve more sight at the moment it converts.¹¹

How Fishtown Medicine thinks about eye aging in Philadelphia

We treat the eye as part of the body, because the macula ages by the same rules as the heart and brain. When eye aging comes up, our first move is to ask the questions that matter rather than hand you a supplement: Do you smoke? What does your diet look like? What is your family history, and when did you last have a dilated eye exam? Those answers do more for your vision than any bottle.

When macular degeneration is a concern, we make sure you are staged by an eye doctor, because that diagnosis is what decides whether AREDS2 belongs in your regimen or is a waste of money. If you do have intermediate or advanced disease, we help you use the correct, beta-carotene-free formula and pair it with the habits that lower risk. And because the retina depends on healthy small vessels, the work we already do on your blood pressure, metabolic health, and fitness is eye care too. When a specialist is needed for monitoring or treatment, we coordinate with highly qualified eye specialists who are in network for you, whether you are in Fishtown or Cherry Hill.

Guidance from the Clinic

"Patients bring me AREDS2 bottles all the time, usually people with no eye disease who bought them to prevent macular degeneration. What I want them to know is that those vitamins were built for a specific job, slowing the disease in someone who already has the intermediate or advanced stage, and they do nothing for a healthy macula. If your eyes are fine, save your money and put the effort where it counts: do not smoke, eat like the Mediterranean, and keep your blood pressure in line. And if it runs in your family, get a dilated exam so we know your stage. That single visit tells us whether the bottle is medicine for you or a needless expense."

Related at Fishtown Medicine

• UV Index in Philadelphia: What to Do - sunglasses and eye protection through the seasons
• Omega-3s: A Clinical Guide - why dietary fish beats the capsule for your eyes
• Ultra-Processed Food: What It Does to Your Health - the diet pattern that ages the small vessels feeding the retina
• ApoB and Heart Health - the vascular health the macula shares
• Foundational Supplements - which supplements earn a place, and which do not

Scientific References

1. Age-Related Eye Disease Study Research Group. "A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8." Archives of Ophthalmology. 2001;119(10):1417-1436.
2. Age-Related Eye Disease Study 2 (AREDS2) Research Group. "Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the AREDS2 randomized clinical trial." JAMA. 2013;309(19):2005-2015.
3. Age-Related Eye Disease Study 2 (AREDS2) Research Group; Chew EY, Clemons TE, Agrón E, et al. "Long-term outcomes of adding lutein/zeaxanthin and omega-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 report 28." JAMA Ophthalmology. 2022;140(7):692-698.
4. Wong WL, Su X, Li X, et al. "Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis." The Lancet Global Health. 2014;2(2):e106-e116.
5. Rein DB, Wittenborn JS, Burke-Conte Z, et al. "Prevalence of age-related macular degeneration in the US in 2019." JAMA Ophthalmology. 2022;140(12):1202-1208.
6. Merle BMJ, Colijn JM, Cougnard-Grégoire A, et al. "Mediterranean diet and incidence of advanced age-related macular degeneration: the EYE-RISK consortium." Ophthalmology. 2019;126(3):381-390.
7. Omenn GS, Goodman GE, Thornquist MD, et al. "Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease." New England Journal of Medicine. 1996;334(18):1150-1155.
8. Chong EW, Kreis AJ, Wong TY, Simpson JA, Guymer RH. "Dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: a systematic review and meta-analysis." Archives of Ophthalmology. 2008;126(6):826-833.
9. Heier JS, Lad EM, Holz FG, et al. "Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials." The Lancet. 2023;402(10411):1434-1448.
10. Khanani AM, Patel SS, Staurenghi G, et al. "Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results of a randomised, double-masked, phase 3 trial." The Lancet. 2023;402(10411):1449-1458.
11. Chew EY, Clemons TE, Bressler SB, et al. "Randomized trial of a home monitoring system for early detection of choroidal neovascularization (Home Monitoring of the Eye [HOME] study)." Ophthalmology. 2014;121(2):535-544.
12. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. "Smoking and age-related macular degeneration: a review of association." Eye. 2005;19(9):935-944.
13. Chakravarthy U, Wong TY, Fletcher A, et al. "Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis." BMC Ophthalmology. 2010;10:31.